Polyostotic fibrous dysplasia
Polyostotic fibrous dysplasia is a rare bone disease that is characterized by the replacement of medullary bone with fibrous tissue, leading to the formation of lesions in one or more bones. The severity of the disease can vary greatly from patient to patient, with some experiencing only mild symptoms and others suffering from severe disability.
Symptoms[edit | edit source]
The symptoms of polyostotic fibrous dysplasia can vary greatly depending on the number and location of the bones affected. Common symptoms include bone pain, bone deformities, fractures, and endocrine abnormalities such as precocious puberty in girls. Other potential symptoms include skin pigmentation and vision and hearing problems.
Causes[edit | edit source]
Polyostotic fibrous dysplasia is caused by a mutation in the GNAS1 gene. This gene provides instructions for producing a protein that helps regulate the activity of many other proteins in the body. The mutation leads to the overactivity of these proteins in certain cells, which can lead to the formation of fibrous dysplasia lesions.
Diagnosis[edit | edit source]
The diagnosis of polyostotic fibrous dysplasia is typically made based on a combination of clinical findings, radiographic studies, and sometimes, a bone biopsy. Magnetic resonance imaging (MRI) and computed tomography (CT) scans can be used to identify lesions in the bones.
Treatment[edit | edit source]
There is currently no cure for polyostotic fibrous dysplasia. Treatment is aimed at managing symptoms and preventing complications. This may include pain management, physical therapy, and surgery to correct bone deformities or fractures. In some cases, medication may be used to slow the progression of the disease.
See also[edit | edit source]
Polyostotic fibrous dysplasia Resources | ||
---|---|---|
|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD